© 2001 European Society of Cardiology
Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice
a Clinical Research Initiative in Heart Failure Glasgow, Scotland G11 6NT, UK
b L'Hôpital Beaujon Clichy, France
c Franz-Volhard-Klinik Berlin, Germany
d VA Hospital Dallas, TX, USA
e University Hosptial Malmo, Sweden
f Department of Primary Care and General Practice Birmingham, UK
g Research Centre Anmco Florence, Italy
h University Hospital Cleveland, USA
i Vall d'Hebron University Barcelona, Spain
j Department of Medicine, Sahlgrenska Hospital/Östra Goteborg, Sweden
* Corresponding author. Tel.: +44-141-330-6588; fax: +44-141-330-6588. E-mail address: j.mcmurray{at}bio.gla.ac.uk (J. McMurray).
 |
Abstract |
|---|
Surveys of prescribing in both hospitals and primary care have shown delays in translating improved survival data from clinical trials into clinical practice thereby denying patients the benefits of proven treatments, such as the angiotensin converting enzyme inhibitors. This may be due to unfamiliarity with clinical guidelines and concerns about adverse events. Recent trials have shown that substantial improvements in survival are associated with spironolactone and beta-blocker therapy. In order to accelerate the uptake of these treatments, and to ensure that all eligible patients should receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of heart failure. The objective of these recommendations is to provide practical guidance for non-specialists in order to support the implementation of evidenced-based therapy for heart failure. These practical recommendations are meant to supplement rather than replace existing guidelines.
Key Words: Clinical recommendations • Beta-blockers • Angiotensin converting enzyme inhibitors • Spironolactone • Heart failure
Received June 1, 2001; Accepted June 25, 2001
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W S A Smellie, J Forth, J J Coleman, W Irvine, P C Dore, G Handley, D G Williams, P J Galloway, K G Kerr, R Herriot, et al. Best practice in primary care pathology: review 6 J. Clin. Pathol., March 1, 2007; 60(3): 225 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Martin and J. J Coleman Monitoring renal function in hypertension. BMJ, October 28, 2006; 333(7574): 896 - 899. [Full Text] [PDF]
|
|
|
|
 |
|
 J. McMurray, A. Cohen-Solal, R. Dietz, E. Eichhorn, L. Erhardt, F.D. R. Hobbs, H. Krum, A. Maggioni, R. S. McKelvie, I. L. Pina, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice Eur J Heart Fail, August 1, 2005; 7(5): 710 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schuchert and On behalf of the BISEX Investigators (Appendix A) Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians Eur J Heart Fail, June 1, 2005; 7(4): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Young, M. E. Dunlap, M. A. Pfeffer, J. L. Probstfield, A. Cohen-Solal, R. Dietz, C. B. Granger, J. Hradec, J. Kuch, R. S. McKelvie, et al. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low-Left Ventricular Ejection Fraction Trials Circulation, October 26, 2004; 110(17): 2618 - 2626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Task Force Members, J. Lopez-Sendon, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: The Task Force on ACE-inhibitors of the European Society of Cardiology Eur. Heart J., August 2, 2004; 25(16): 1454 - 1470. [Full Text] [PDF]
|
|
|
|
|
|
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Metra, S. Nodari, and L. Dei Cas Current guidelines in the pharmacological management of chronic heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S11 - S16. [Abstract] [PDF]
|
|
|
|
 |
|
 D B McKenzie and A J Cowley Drug therapy in chronic heart failure Postgrad. Med. J., November 1, 2003; 79(937): 634 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R Cowie and A. Zaphiriou Recent developments: Management of chronic heart failure BMJ, August 24, 2002; 325(7361): 422 - 425. [Full Text] [PDF]
|
|
|
|
|
|
J. McMurray and M. A. Pfeffer New Therapeutic Options in Congestive Heart Failure: Part II Circulation, May 7, 2002; 105(18): 2223 - 2228. [Full Text] [PDF]
|
|
|
|
 |
|
 J.J.V McMurray and S Stewart The burden of heart failure Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D50 - D58. [Abstract] [PDF]
|
|